HOUSTON — In patients with asthma, benralizumab is associated with substantial improvements in total scores on the St. George’s Respiratory Questionnaire (SGRQ), with similar improvements seen across all domains, according to research presented at the American College of Allergy, Asthma, & Immunology 2019 Annual Scientific Meeting, held November 7 to 11, in Houston, Texas.

SOLANA (ClinicalTrials.gov Identifier: NCT02869438) was a 12-week, multinational, double-blind, randomized, placebo-controlled Phase 3b onset-of-effect characterization study. It was also the first study of benralizumab to include the SGRQ, a 50-item respiratory health status assessment tool. Total and domain (activity, symptom, and psychosocial impact) scores are weighted and expressed as percentages, with larger values indicating a greater degree of impairment. This post hoc analysis of the total and domain SGRQ scores for SOLANA participants who had baseline blood eosinophil counts of ≥300 cells/µL was designed to evaluate the effect onset and maintenance among participants receiving benralizumab compared with placebo.

The improvements seen in total and domain SGRQ scores were greater among participants receiving benralizumab compared with placebo as early as 4 weeks into treatment. By week 4, least squares mean differences in change from baseline with benralizumab vs placebo were -7.23 (95% CI, -10.83 to -3.63) for total scores, -7.87 (95% CI, -13.06 to -2.69) for symptom scores, -8.52 (95% CI, -13.40 to -3.63) for activity scores, and -6.05 (95% CI, -9.73 to -2.38) for psychosocial impact scores (P <.005 for all). Score improvements with benralizumab compared with placebo remained consistent across all domains at all time points post baseline.

Continue Reading

Related Articles

Study investigators concluded that benralizumab is associated with improvements in total and domain SGRQ scores, observed by week 4 and persisting through all time points.


O’Quinn, Hirsch I, Cook W, Martin U. Improvements in SGRQ total and domain scores with benralizumab treatment for patients with asthma. Presented at: American College of Allergy, Asthma, & Immunology Annual Scientific Meeting 2019; November 7-11, 2019; Houston, TX. Abstract P108.